Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This multimodal analgesic combination, often referred to as a 'protracted mixture,' consists of the local anesthetic bupivacaine (Marcaine), the vasoconstrictor epinephrine (adrenaline), the alpha-2 adrenergic agonist clonidine, and the synthetic corticosteroid dexamethasone. It was specifically evaluated in a Phase 4 randomized clinical trial (Hobsali) conducted by Regionshospitalet Silkeborg for the management of postoperative pain following total knee arthroplasty. In this context, dexamethasone acts as a glucocorticoid adjuvant that prolongs the duration of sensory nerve blocks and reduces systemic inflammatory responses. The combination is administered via saphenous and obturator nerve blocks to provide extended analgesia, reduce postoperative opioid consumption, and minimize associated side effects such as nausea and vomiting.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine + epinephrine + clonidine + dexamethasone.